Forward Citations = 10

Loading Chart...

1 inventor (with patents filed for the assignee):

James A Radosevich (4 out of 9 patents)

4 patents: Sort by Forward Citations

1. 7635759 - Gene encoding labyrinthin, a marker for cancer (2009-12-22),

2. 7329743 - Gene encoding labyrinthin, a marker for cancer (2008-02-12),

3. 6727080 - Gene encoding labyrinthin, a marker for cancer (2004-04-27),

4. 6166176 - Cancer marker protein and peptides thereof (2000-12-26),

Immvarx, Inc. is a biotechnology company dedicated to developing innovative immunotherapies for cancer. They are focused on harnessing the power of the immune system to target and destroy cancer cells, with a mission to improve patient outcomes and quality of life. Immvarx's pipeline includes a range of novel therapies designed to activate and enhance the body's natural defenses against cancer. Through cutting-edge research and strategic partnerships, Immvarx is at the forefront of the oncology field, working towards a future where cancer is a manageable chronic disease.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

4 Patents

#355 in Palo Alto, CA

#13,684 in California

#59,078 in US

Palo Alto, CA, United States of America

Immvarx, Inc.

Forward Citations = 10

1 inventor:

James A Radosevich (4 out of 9 patents)

Please report any incorrect information to support@idiyas.com